Michelle Middle

Michelle Middle has a diverse work experience in the field of clinical development and trials. Michelle currently works as the Medical Director of Clinical Development at SCYNEXIS, Inc. since May 2021. Prior to that, Michelle held the role of Managing Director and Clinical Trials Consultant at South Africa Clinical Trials Consulting from October 2016 to July 2021. Michelle also served as the Chief Medical Officer at FARMOVS Pty Ltd from July 2018 to October 2020. Before that, Michelle worked as a Medical Advisor and BD Executive at Synexus Clinical Research Ltd from September 2012 to July 2016. Michelle was also the CEO of Qdotpharma. from September 2011 to July 2012. Michelle's earlier experience includes serving as the Corporate VP and Worldwide Head of Early Phase and Early Product Development at PAREXEL from 2008 to 2011.

Michelle Middle has an extensive education history in the field of medicine and pharmaceuticals. Michelle first obtained a medical degree, an MB.ChB, from the University Orange Free State in South Africa, where they studied from 1983 to 1989. Following this, Michelle pursued further education at Hibernia College, where they obtained a Master's Degree in Pharmaceutical Medicine from 2013 to 2016.

In 2016, Michelle enrolled at the James Lind Institute, where they pursued an Advanced Post Graduate Diploma in Pharmacovigilance and Medical Writing, specializing in Clinical Research. Michelle successfully completed this program in 2017.

In addition to these academic achievements, Michelle has obtained additional certifications. Michelle received an Advanced Post Graduate Diploma in Pharmacovigilance and Medical Writing from the James Lind Institute in November 2016. Michelle also holds a medical degree and a Masters in Pharmaceutical Medicine, although the specific details regarding the institution and year of acquisition are not specified.